Study analysis · Cancers · 2026
This app helped cancer survivors feel more in control—but didn’t make them feel better overall.
A phone app helped stomach cancer patients feel like they were managing their recovery better, but their overall quality of life didn’t improve compared to regular care.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study tried out a new app to help people feel better after stomach cancer surgery, but it didn't clearly make them feel better overall. It did show that lots of people liked using the app and stuck with it, which is good—but that doesn't mean the app fixed their symptoms.
What’s the bottom line?
After stomach cancer surgery, patients often feel unwell and need help managing symptoms at home. This study tested a phone app that asked patients daily about their symptoms and gave them personalized tips on food, exercise, and coping.
How strong is this study?
The study did a good job randomly assigning people to groups and asking the same questions over time, which makes it trustworthy. But it was too small and only lasted six months, so we can't be sure if the app really helps or if the results were just luck.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
63 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample size (n=66)+5.6/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 575 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Although this is a randomized controlled trial, the primary endpoint was not statistically significant (p = 0.603), the sample size was small (n=66), and the study was explicitly labeled a pilot trial with no formal power calculation. These factors severely limit the ability to draw causal conclusions about the platform's efficacy.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were explicitly stated in the text, and there is no evidence of industry involvement or author affiliations that suggest bias.
Independent Analysis Safeguards
- Randomization was performed by an independent statistician using a computer-generated allocation sequence.
- Allocation concealment was maintained through a centralized computer-based system.
- Statistical analysis was conducted using linear mixed-effects models with predefined methods, and analyses were performed in R by an unspecified team without indication of funder influence.
Although no COI or funding statement is present, the study was conducted by an academic research group (KOQUSS Study Group) affiliated with the Korean Gastric Cancer Association, and no industry sponsors, authors' industry ties, or funder roles in design, analysis, or publication are indicated. The absence of a disclosure section is a limitation, but no red flags for bias are present in the methodology or reporting.
Key takeaways
- 01
87% of patients used the app regularly, 82% were happy with it, and 77% felt more in control of their recovery.
- 02
But their overall quality of life scores didn’t improve more than those getting regular care.
- 03
Even though the app didn’t boost overall quality of life scores, patients felt more confident managing their symptoms — which matters for daily life.
Surprising findings
- High adherence (86.7%) and satisfaction (82%) didn’t lead to a significant improvement in quality of life.Most digital health studies assume high engagement equals better outcomes—this flips that logic, showing you can love a tool and still not get clinically better.
- The control group received such high-quality standard care that it masked any potential benefit from the app.It’s rare for standard care to be so good that a flashy digital tool can’t outperform it—this suggests the app’s value may lie in low-resource settings, not elite hospitals.
Practical takeaways
If you’re a gastric cancer survivor, try a symptom-tracking app—even if it doesn’t magically improve your scores, it might help you feel more in control.
Don’t expect miracles: this study shows no significant improvement in overall quality of life, and results may not apply outside high-resource healthcare systems.
medium confidenceWhy this study matters
87% Used It Daily—But Still No Big Improvement
86.7% of patients stuck with the WECARE app for six months, and 82% said they were satisfied—but the main measure of quality of life (KOQUSS-40) showed no statistically significant difference from standard care (p=0.603).
People assume if patients love an app and use it constantly, it must be helping them feel better—but this study proves engagement doesn’t always translate to measurable health gains.
They Felt More in Control—Even If They Didn’t Feel Better
77% of users reported the app improved their self-management capabilities, meaning they felt more confident handling symptoms like reflux or diet changes—even though their KOQUSS-40 scores didn’t rise.
This reveals a hidden win: digital tools can boost psychological empowerment even when clinical outcomes stay flat—a huge deal for chronic illness management.
Reflux Got Better—Just Not Enough to Count
The app showed a trend toward improved reflux symptom management (p=0.0856)—just shy of statistical significance—suggesting it might help with specific post-surgery issues.
It hints that digital tools may be precision weapons for specific symptoms, not broad quality-of-life boosters—a game-changer for targeted health tech design.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
After stomach cancer surgery, patients often feel unwell and need help managing symptoms at home. This study tested a phone app that asked patients daily about their symptoms and gave them personalized tips on food, exercise, and coping.
Research results
87% of patients used the app regularly, 82% were happy with it, and 77% felt more in control of their recovery. But their overall quality of life scores didn’t improve more than those getting regular care.
What this means - more context
Even though the app didn’t boost overall quality of life scores, patients felt more confident managing their symptoms — which matters for daily life.
This study evaluated whether a digital symptom management platform (WECARE) improves quality of life in gastric cancer survivors after gastrectomy compared to standard care.
The WECARE platform showed high feasibility (86.7% adherence) and patient satisfaction (82%), with improved self-management perceptions (77%) and a trend toward better reflux control (p=0.0856), but no statistically significant improvement in overall quality of life (KOQUSS-40, p=0.603).
Methods Used
Nationwide multicenter pilot randomized controlled trial with 66 randomized patients (1:1 allocation); intervention group used a digital platform integrating KOQUSS-40 symptom reporting with personalized feedback on nutrition, exercise, and symptom coping; outcomes measured at baseline, 1, 3, and 6 months.
Main Finding
No significant difference in KOQUSS-40 total score at 6 months between WECARE and control groups (mean difference 1.5 points, p=0.603, Cohen’s d=-0.065), though WECARE showed a numerically favorable recovery trajectory and high engagement.
Confidence Level
Moderate — pilot RCT with small sample size (n=66), limited power to detect small effects; baseline sex imbalance noted; high adherence and validated tools support reliability of feasibility outcomes.
Study Flags
Red Flags
- •Small sample size (n=66) limiting statistical power
- •Baseline sex imbalance between groups (p=0.04)
- •High standard of control group care may mask intervention benefit
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
High adherence (86.7%) and satisfaction (82%) didn’t lead to a significant improvement in quality of life.
Most digital health studies assume high engagement equals better outcomes—this flips that logic, showing you can love a tool and still not get clinically better.
Practical Takeaways
If you’re a gastric cancer survivor, try a symptom-tracking app—even if it doesn’t magically improve your scores, it might help you feel more in control.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 575 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study tried out a new app to help people feel better after stomach cancer surgery, but it didn't clearly make them feel better overall. It did show that lots of people liked using the app and stuck with it, which is good—but that doesn't mean the app fixed their symptoms.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized controlled design with concealed allocation
- Multicenter recruitment across nine tertiary hospitals
- Use of validated outcome measure (KOQUSS-40)
Weaknesses
- Pilot study with no formal sample size calculation
- Small sample size (n=66) leading to low statistical power
- No blinding of participants or clinicians
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
After stomach cancer surgery, patients often feel unwell and need help managing symptoms at home. This study tested a phone app that asked patients daily about their symptoms and gave them personalized tips on food, exercise, and coping.
Research results
87% of patients used the app regularly, 82% were happy with it, and 77% felt more in control of their recovery. But their overall quality of life scores didn’t improve more than those getting regular care.
What this means - more context
Even though the app didn’t boost overall quality of life scores, patients felt more confident managing their symptoms — which matters for daily life.
This study evaluated whether a digital symptom management platform (WECARE) improves quality of life in gastric cancer survivors after gastrectomy compared to standard care.
The WECARE platform showed high feasibility (86.7% adherence) and patient satisfaction (82%), with improved self-management perceptions (77%) and a trend toward better reflux control (p=0.0856), but no statistically significant improvement in overall quality of life (KOQUSS-40, p=0.603).
Methods Used
Nationwide multicenter pilot randomized controlled trial with 66 randomized patients (1:1 allocation); intervention group used a digital platform integrating KOQUSS-40 symptom reporting with personalized feedback on nutrition, exercise, and symptom coping; outcomes measured at baseline, 1, 3, and 6 months.
Main Finding
No significant difference in KOQUSS-40 total score at 6 months between WECARE and control groups (mean difference 1.5 points, p=0.603, Cohen’s d=-0.065), though WECARE showed a numerically favorable recovery trajectory and high engagement.
Confidence Level
Moderate — pilot RCT with small sample size (n=66), limited power to detect small effects; baseline sex imbalance noted; high adherence and validated tools support reliability of feasibility outcomes.
Study Flags
Red Flags
- •Small sample size (n=66) limiting statistical power
- •Baseline sex imbalance between groups (p=0.04)
- •High standard of control group care may mask intervention benefit
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
High adherence (86.7%) and satisfaction (82%) didn’t lead to a significant improvement in quality of life.
Most digital health studies assume high engagement equals better outcomes—this flips that logic, showing you can love a tool and still not get clinically better.
Practical Takeaways
If you’re a gastric cancer survivor, try a symptom-tracking app—even if it doesn’t magically improve your scores, it might help you feel more in control.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 575 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study tried out a new app to help people feel better after stomach cancer surgery, but it didn't clearly make them feel better overall. It did show that lots of people liked using the app and stuck with it, which is good—but that doesn't mean the app fixed their symptoms.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized controlled design with concealed allocation
- Multicenter recruitment across nine tertiary hospitals
- Use of validated outcome measure (KOQUSS-40)
Weaknesses
- Pilot study with no formal sample size calculation
- Small sample size (n=66) leading to low statistical power
- No blinding of participants or clinicians
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study did a good job randomly assigning people to groups and asking the same questions over time, which makes it trustworthy. But it was too small and only lasted six months, so we can't be sure if the app really helps or if the results were just luck.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
63 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample size (n=66)+5.6/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 575 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Although this is a randomized controlled trial, the primary endpoint was not statistically significant (p = 0.603), the sample size was small (n=66), and the study was explicitly labeled a pilot trial with no formal power calculation. These factors severely limit the ability to draw causal conclusions about the platform's efficacy.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were explicitly stated in the text, and there is no evidence of industry involvement or author affiliations that suggest bias.
Independent Analysis Safeguards
- Randomization was performed by an independent statistician using a computer-generated allocation sequence.
- Allocation concealment was maintained through a centralized computer-based system.
- Statistical analysis was conducted using linear mixed-effects models with predefined methods, and analyses were performed in R by an unspecified team without indication of funder influence.
Although no COI or funding statement is present, the study was conducted by an academic research group (KOQUSS Study Group) affiliated with the Korean Gastric Cancer Association, and no industry sponsors, authors' industry ties, or funder roles in design, analysis, or publication are indicated. The absence of a disclosure section is a limitation, but no red flags for bias are present in the methodology or reporting.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
14 researchersIf this is your work, this is how we attribute it on Fit Body Science. Geum Jong Song is listed as the lead author.